


## Supplementary appendix 12. Inconsistency.

---


Plot of the individual data points' posterior mean deviance contributions for the consistency model (horizontal axis) and the inconsistency model (vertical axis) along with the line of equality for outcome of any bleeding. Points which have a better fit in the inconsistency model have been marked with the trial name.



Left figure, 30 trials were included; Right figure, trials of ECLIPse and CAIST were excluded; Left figure shows that likely sources of inconsistency were the ECLIPse and CAIST trials.

## Supplementary appendix 12. Inconsistency.

### Inconsistency plot.



(A) serious vascular events; (B) recurrent stroke; (C) any bleeding; (D) any bleeding (ECLIPse and CAIST trials were excluded). ROR, ratio of two odds ratios. ROR values close to 1 mean that direct evidence and indirect evidence are in agreement. D, dipyridamole; P, placebo; TF, triflusal; TC, ticlopidine; CL, cilostazol; C, clopidogrel; A1, aspirin (30–50 mg) daily; A2, aspirin (75–162 mg) daily; A3, aspirin (283–330 mg) daily; A4, aspirin (500–1500 mg) daily; AD1, aspirin (50 mg) plus dipyridamole (400 mg) daily; AD2, aspirin (990–1300 mg) plus dipyridamole (150–300 mg) daily.

## Supplementary appendix 12. Inconsistency.

Network meta-analysis of different antiplatelet regimens for any bleeding. ECLIPse and CAIST trials were excluded.

Comparisons	OR (96% CrI)	Comparisons	OR (96% CrI)	Comparisons	OR (96% CrI)	Comparisons	OR (96% CrI)	Comparisons	OR (96% CrI)
P vs D	0.98 (0.67-1.52)	D vs C	1.83 (1.13-2.88)	A2 vs A+TC	1.21 (0.25-3.53)	A4 vs TF	0.47 (0.28-0.78)	TC vs CL	0.45 (0.27-0.85)
P vs A1	1.76 (1.25-2.43)	D vs A+C	5.21 (3.31-8.16)	A2 vs C	0.79 (0.57-1.08)	A4 vs CL	0.35 (0.21-0.63)	TC vs A+CL	0.35 (0.07-3.45)
P vs A2	2.27 (1.69-3.13)	D vs TF	1.36 (0.71-2.21)	A2 vs A+C	2.23 (1.77-2.88)	A4 vs A+CL	0.28 (0.06-2.63)	A+TC vs C	0.64 (0.22-3.13)
P vs A3	2.53 (1.80-3.49)	D vs CL	1.03 (0.58-1.73)	A2 vs TF	0.59 (0.33-0.89)	AD1 vs AD2	1.31 (0.66-2.37)	A+TC vs A+C	1.82 (0.63-9.09)
P vs A4	2.78 (1.91-3.86)	D vs A+CL	2.00 (0.16-7.21)	A2 vs CL	0.44 (0.29-0.64)	AD1 vs TC	1.12 (0.67-1.69)	A+TC vs TF	0.75 (0.15-2.30)
P vs AD1	1.96 (1.45-2.70)	A1 vs A2	1.30 (0.93-1.92)	A2 vs A+CL	0.86 (0.07-3.04)	AD1 vs A+TC	1.42 (0.30-4.11)	A+TC vs CL	0.35 (0.12-1.82)
P vs AD2	2.55 (1.35-4.44)	A1 vs A3	1.45 (1.05-1.98)	A3 vs A4	1.11 (0.74-1.60)	AD1 vs C	0.92 (0.69-1.23)	A+TC vs A+CL	0.28 (0.05-5.26)
P vs TC	2.19 (1.41-3.13)	A1 vs A4	1.61 (1.02-2.41)	A3 vs AD1	0.78 (0.56-1.11)	AD1 vs A+C	2.63 (1.99-3.57)	C vs A+C	2.89 (2.12-3.95)
P vs A+TC	2.77 (0.60-7.97)	A1 vs AD1	1.11 (0.81-1.56)	A3 vs AD2	1.03 (0.53-1.83)	AD1 vs TF	0.69 (0.39-1.04)	C vs TF	0.76 (0.41-1.19)
P vs C	1.75 (1.25-2.63)	A1 vs AD2	1.48 (0.74-2.70)	A3 vs TC	0.83 (0.53-1.32)	AD1 vs CL	0.52 (0.33-0.79)	C vs CL	0.58 (0.34-0.90)
P vs A+C	5.00 (3.70-7.14)	A1 vs TC	1.19 (0.74-1.92)	A3 vs A+TC	0.71 (0.23-3.23)	AD1 vs A+CL	1.01 (0.08-3.59)	C vs A+CL	1.11 (0.09-3.92)
P vs TF	1.35 (0.79-2.05)	A1 vs A+TC	1.02 (0.33-4.76)	A3 vs C	0.70 (0.49-1.08)	AD2 vs TC	0.84 (0.47-1.54)	A+C vs TF	0.27 (0.15-0.40)
P vs CL	0.98 (0.65-1.56)	A1 vs C	1.01 (0.70-1.56)	A3 vs A+C	2.00 (1.49-2.94)	AD2 vs A+TC	0.71 (0.23-3.45)	A+C vs CL	0.19 (0.13-0.30)
P vs A+CL	0.76 (0.16-7.14)	A1 vs A+C	2.86 (2.08-4.35)	A3 vs TF	0.52 (0.36-0.71)	AD2 vs C	0.69 (0.38-1.43)	A+C vs A+CL	0.38 (0.03-1.34)
D vs A1	1.77 (1.15-2.60)	A1 vs TF	0.74 (0.45-1.16)	A3 vs CL	0.39 (0.25-0.66)	AD2 vs A+C	2.00 (1.10-4.00)	TF vs CL	0.72 (0.43-1.45)
D vs A2	2.22 (1.49-3.57)	A1 vs CL	0.56 (0.35-0.95)	A3 vs A+CL	0.31 (0.06-2.86)	AD2 vs TF	0.51 (0.26-1.06)	TF vs A+CL	0.58 (0.12-5.56)
D vs A3	2.55 (1.58-3.90)	A1 vs A+CL	0.44 (0.09-4.00)	A4 vs AD1	0.70 (0.47-1.10)	AD2 vs CL	0.38 (0.20-0.85)	CL vs A+CL	2.02 (0.16-7.74)
D vs A4	2.81 (1.63-4.52)	A2 vs A3	1.10 (0.76-1.52)	A4 vs AD2	0.92 (0.55-1.48)	AD2 vs A+CL	0.30 (0.06-3.23)		
D vs AD1	1.92 (1.32-2.94)	A2 vs A4	1.21 (0.77-1.80)	A4 vs TC	0.78 (0.56-1.04)	TC vs A+TC	1.27 (0.30-3.54)		
D vs AD2	2.58 (1.21-4.93)	A2 vs AD1	0.86 (0.66-1.08)	A4 vs A+TC	0.66 (0.22-2.86)	TC vs C	0.81 (0.52-1.43)		
D vs TC	2.21 (1.20-3.60)	A2 vs AD2	1.12 (0.56-2.02)	A4 vs C	0.64 (0.42-1.05)	TC vs A+C	2.33 (1.52-4.00)		
D vs A+TC	2.80 (0.56-8.43)	A2 vs TC	0.96 (0.57-1.45)	A4 vs A+C	1.82 (1.23-2.94)	TC vs TF	0.64 (0.35-1.06)		

Random effects model was used; 28 studies were included; A, aspirin; D, dipyridamole; AD, aspirin plus dipyridamole; P, placebo; TF, triflusal; TC, ticlopidine; CL, cilostazol; C, clopidogrel; A2, aspirin 75-162 mg daily; A1, aspirin 30-50 mg daily; A3, aspirin 283-330 mg daily; A4, aspirin 500-1500 mg daily; AD1, aspirin 50 mg plus dipyridamole 400 mg daily; AD2, aspirin 990-1300 mg plus dipyridamole 150-300 mg daily; comparisons between regimens should be read from right to left; for all of the table cells, odds ratios <1 favor the right regimens.